Literature DB >> 16310605

Burden of illness in venous thromboembolism in critical care: a multicenter observational study.

Rakesh Patel1, Deborah J Cook, Maureen O Meade, Lauren E Griffith, Geeta Mehta, Graeme M Rocker, John C Marshall, Rick Hodder, Claudio M Martin, Daren K Heyland, Sharon Peters, John Muscedere, Mark Soth, Nicole Campbell, Gordon H Guyatt.   

Abstract

PURPOSE: The frequency of clinically diagnosed venous thromboembolism (VTE) including deep venous thrombosis (DVT) and pulmonary embolism (PE) in medical-surgical critically ill patients is unclear. The objectives of this study were to estimate the prevalence and incidence of radiologically confirmed DVT and PE in medical-surgical intensive care unit (ICU) patients and to determine the impact of prophylaxis on the frequency of these events.
MATERIALS AND METHODS: In a retrospective observational cohort study in 12 adult ICUs, we identified prevalent cases (diagnosed in the 24 hours preceding ICU admission up to 48 hours post-ICU admission) and incident cases (diagnosed 48 hours or more after ICU admission and up to 8 weeks after ICU discharge) of upper or lower limb DVT or PE. Deep venous thrombosis was diagnosed by compression ultrasound or venogram. Each DVT was classified as clinically suspected or not clinically suspected in that the latter was diagnosed by scheduled screening ultrasonography. Pulmonary embolism was diagnosed by ventilation-perfusion lung scan, computed tomography pulmonary angiography, echocardiography, electrocardiography, or autopsy.
RESULTS: Among 12,338 patients, 252 (2.0%) patients had radiologically confirmed DVT or PE and another 47 (0.4%) had possible DVT or PE. Prevalent DVTs were diagnosed in 0.4% (95% confidence interval [CI], 0.3%-0.5%) of patients and prevalent PEs were diagnosed in 0.4% (95% CI, 0.3%-0.6%). Incident DVTs were diagnosed in 1.0% (95% CI, 0.8%-1.2%) of patients, and incident PEs were diagnosed in 0.5% (95% CI, 0.4%-0.6%). Of patients with incident VTE, 65.8% of cases occurred despite receipt of thromboprophylaxis for at least 80% of their days in ICU. The median (interquartile range) ICU length of stay was similar for patients with DVT (7 [3-17]) and PE (5 [2-8]). For all patients with VTE, ICU mortality was 16.7% (95% CI, 12.0%-21.3%) and hospital mortality was 28.5% (95% CI, 22.8%-34.1%).
CONCLUSIONS: Venous thromboembolism appears to be an apparently infrequent, but likely underdiagnosed problem, occurring among patients receiving prophylaxis. Findings suggest the need for increased suspicion among clinicians, renewed efforts at thromboprophylaxis, and evaluation of superior prevention strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16310605     DOI: 10.1016/j.jcrc.2005.09.014

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  21 in total

1.  Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis.

Authors:  D Cook; Y Arabi; N Ferguson; D Heels-Ansdell; A Freitag; E McDonald; F Clarke; S Keenan; G Pagliarello; W Plaxton; M Herridge; T Karachi; S Vallance; J Cade; T Crozier; S Alves da Silva; R Costa Filho; N Brandao; I Watpool; T McArdle; G Hollinger; Y Mandourah; M Al-Hazmi; N Zytaruk; N K J Adhikari
Journal:  Intensive Care Med       Date:  2013-12       Impact factor: 17.440

Review 2.  Coagulation abnormalities in the trauma patient: the role of point-of-care thromboelastography.

Authors:  Eduardo Gonzalez; Fredric M Pieracci; Ernest E Moore; Jeffry L Kashuk
Journal:  Semin Thromb Hemost       Date:  2010-10-26       Impact factor: 4.180

3.  Recovery from Coma Post-Cardiac Arrest Is Dependent on the Orexin Pathway.

Authors:  Young-Jin Kang; Guilian Tian; Afsheen Bazrafkan; Maryam H Farahabadi; Matine Azadian; Hamidreza Abbasi; Brittany E Shamaoun; Oswald Steward; Yama Akbari
Journal:  J Neurotrauma       Date:  2017-06-16       Impact factor: 5.269

Review 4.  The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes.

Authors:  Alessandra Malato; Francesco Dentali; Sergio Siragusa; Francesco Fabbiano; Yoan Kagoma; Maria Boddi; Gian Franco Gensini; Adriano Peris; Mark Crowther; Mariasanta Napolitano
Journal:  Blood Transfus       Date:  2015-10       Impact factor: 3.443

5.  A multinational study of thromboprophylaxis practice in critically ill children.

Authors:  Edward Vincent S Faustino; Sheila Hanson; Philip C Spinella; Marisa Tucci; Sarah H O'Brien; Antonio Rodriguez Nunez; Michael Yung; Edward Truemper; Li Qin; Simon Li; Kimberly Marohn; Adrienne G Randolph
Journal:  Crit Care Med       Date:  2014-05       Impact factor: 7.598

6.  Intensive care unit capacity strain and adherence to prophylaxis guidelines.

Authors:  Gary E Weissman; Nicole B Gabler; Sydney E S Brown; Scott D Halpern
Journal:  J Crit Care       Date:  2015-08-22       Impact factor: 3.425

7.  [Thromboprophylaxis in critically ill children in Spain and Portugal].

Authors:  A Rodríguez Núñez; M Fonte; E V S Faustino
Journal:  An Pediatr (Barc)       Date:  2014-06-05       Impact factor: 1.500

8.  Differentiation of enzymatic from platelet hypercoagulability using the novel thrombelastography parameter delta (delta).

Authors:  Eduardo Gonzalez; Jeffry L Kashuk; Ernest E Moore; Christopher C Silliman
Journal:  J Surg Res       Date:  2010-04-21       Impact factor: 2.192

9.  Venous Thromboembolism Prophylaxis in Neurocritical Care Patients: Are Current Practices, Best Practices?

Authors:  K M Sauro; A Soo; A Kramer; P Couillard; J Kromm; D Zygun; D J Niven; S M Bagshaw; H T Stelfox
Journal:  Neurocrit Care       Date:  2019-04       Impact factor: 3.210

Review 10.  Prophylaxis of Venous Thrombosis in Neurocritical Care Patients: An Evidence-Based Guideline: A Statement for Healthcare Professionals from the Neurocritical Care Society.

Authors:  Paul Nyquist; Cynthia Bautista; Draga Jichici; Joseph Burns; Sanjeev Chhangani; Michele DeFilippis; Fernando D Goldenberg; Keri Kim; Xi Liu-DeRyke; William Mack; Kim Meyer
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.